This video is entirely AI generated and does not replicate any original material. It should not be considered a substitute for authentic sources. For complete context and techniques, viewers are encouraged to refer to the original content.
Based on findings from:
-
Predicting TP53 Biomarkers from Whole Slide Images across Human Solid Tumors Using Weakly Supervised Learning
Abadh Chaurasia, et al.. The American Journal of Pathology, 2026.
DOI: 10.1016/j.ajpath.2026.05.008
-
Leave No Data Behind: Exploring a new paradigm in oncology with foundation models and large language models
Federica Corso, et al.. Cell Reports Medicine, 2026.
DOI: 10.1016/j.xcrm.2026.102966
-
Considerations for the Regulation of Generative AI-Enabled Medical Devices: Discussion Paper and Request for Feedback
Weekly News Brief: August 24–28, 2026
To catch up on all of the news from this past week, listen to our weekly news brief for the week of August 24–28, 2026.
This week’s brief covers a framework for bringing fragmented oncology data together in one model approach, a Vision Transformer model for predicting molecular and prognostic features for 32 tumor types, and the FDA seeks feedback on an approach to regulating generative AI–enabled medical devices.
To learn more about Leave No Data Behind, read "From Task-Specific Tools to Generalist Models: Charting Oncology's Next AI Shift, or see the source report in Cell Reports Medicine.
For more information on a multitask, pan-tumor model, read "Multitask Vision Transformer Predicts Molecular and Prognostic Features Across 32 Solid Tumors," or see the source report in The American Journal of Pathology.
To learn more about regulatory considerations for generative AI devices, read "FDA Considering Approach to Regulating Generative AI–Enabled Medical Devices, Seeking Public Feedback," or see the FDA discussion paper.
Disclaimer: This newscast was generated with the assistance of AI tools and avatars. All content is reviewed and approved by the editorial staff of ASCO AI in Oncology. Contact us with any questions.
The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. The mention of any company, product, service, or therapy should not be construed as an endorsement of any kind. Conexiant and ASCO assume no responsibility for any injury or damage to persons or property arising out of or related to any use of material contained in this publication or to any errors or omissions.